DK0956009T3 - Behandling af neurodegenerative tilstande med nimesulid - Google Patents

Behandling af neurodegenerative tilstande med nimesulid

Info

Publication number
DK0956009T3
DK0956009T3 DK97950672T DK97950672T DK0956009T3 DK 0956009 T3 DK0956009 T3 DK 0956009T3 DK 97950672 T DK97950672 T DK 97950672T DK 97950672 T DK97950672 T DK 97950672T DK 0956009 T3 DK0956009 T3 DK 0956009T3
Authority
DK
Denmark
Prior art keywords
nimesulide
treatment
neurodegenerative conditions
neurodegeneration
discovery
Prior art date
Application number
DK97950672T
Other languages
English (en)
Inventor
Sinai School Of Medicine Mount
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Application granted granted Critical
Publication of DK0956009T3 publication Critical patent/DK0956009T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
DK97950672T 1996-11-21 1997-11-19 Behandling af neurodegenerative tilstande med nimesulid DK0956009T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3333296P 1996-11-21 1996-11-21
US08/831,402 US5985930A (en) 1996-11-21 1997-04-01 Treatment of neurodegenerative conditions with nimesulide
PCT/US1997/021484 WO1998022104A2 (en) 1996-11-21 1997-11-19 Treatment of neurodegenerative conditions with nimesulide

Publications (1)

Publication Number Publication Date
DK0956009T3 true DK0956009T3 (da) 2002-05-21

Family

ID=26709565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97950672T DK0956009T3 (da) 1996-11-21 1997-11-19 Behandling af neurodegenerative tilstande med nimesulid

Country Status (18)

Country Link
US (3) US5985930A (da)
EP (1) EP0956009B9 (da)
JP (1) JP2001505206A (da)
KR (1) KR20000069061A (da)
AT (1) ATE212546T1 (da)
AU (1) AU725141B2 (da)
BR (1) BR9714303A (da)
CA (1) CA2272249A1 (da)
DE (1) DE69710224T2 (da)
DK (1) DK0956009T3 (da)
ES (1) ES2172822T3 (da)
IL (1) IL129949A (da)
NO (1) NO992374L (da)
NZ (1) NZ335726A (da)
PT (1) PT956009E (da)
SK (1) SK284334B6 (da)
TR (1) TR199901120T2 (da)
WO (1) WO1998022104A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6441152B1 (en) * 1998-12-08 2002-08-27 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
AU773273B2 (en) * 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
ATE328002T1 (de) 1999-10-13 2006-06-15 Univ Johns Hopkins Med Verbindungen zur regulierung des hedgehog- signalwegs, zusammensetzungen und verwendungen davon
IL156268A0 (en) 2000-12-13 2004-01-04 Wyeth Corp Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
US20040063752A1 (en) * 2002-05-31 2004-04-01 Pharmacia Corporation Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX-2) inhibitor(s)
AU2003237988A1 (en) * 2002-06-13 2003-12-31 Mount Sinai School Of Medicine Of New York University Inhibiting progressive cognitive impairment
AU2003218345A1 (en) * 2002-11-06 2004-06-03 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
RU2342374C2 (ru) 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
US8324450B2 (en) 2009-06-02 2012-12-04 Academia Sinica Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
CN104093833B (zh) 2011-12-16 2017-11-07 斯坦福大学托管董事会 视蛋白多肽及其使用方法
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
WO2015023782A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
EP4276176A3 (en) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
CN106459138A (zh) 2014-03-28 2017-02-22 斯坦福大学托管董事会 工程化的光激活阴离子通道蛋白及其使用方法
EA201691696A1 (ru) * 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
EP3224380A1 (en) 2014-11-25 2017-10-04 The Broad Institute Inc. Clonal haematopoiesis
US11168369B2 (en) 2014-11-25 2021-11-09 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
WO2017040538A1 (en) 2015-08-31 2017-03-09 The Board Of Trustees Of The Leland Stanford Junior University Compressed sensing high resolution functional magnetic resonance imaging
EP3386374A4 (en) 2015-12-09 2019-11-06 The Board of Trustees of the Leland Stanford Junior University METHODS FOR FUNCTIONAL BRAIN CIRCUIT ANALYSIS
WO2017136285A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Method and systems for analyzing functional imaging data
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403096A (en) * 1963-10-02 1968-09-24 Ceskoslovenska Akademie Ved Method and device for separation of a suspension
US4966692A (en) * 1989-05-05 1990-10-30 Flint & Walling, Inc. Filtration system having flow control means and tank adapter with selective venting
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH10506615A (ja) * 1994-07-27 1998-06-30 ザ、プロクター、エンド、ギャンブル、カンパニー 抗炎症剤として有用なジヒドロベンゾフラン及び関連化合物
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CA2164559A1 (en) * 1994-12-09 1996-06-10 Chun-Sing Li 5-methanesulfonamido-6-(2-pyridylthio)-1-indanones as inhibitors of cyclooxygenase-2
JPH10511089A (ja) * 1994-12-21 1998-10-27 メルク フロスト カナダ インコーポレーテツド Ｃｏｘ−２阻害剤としてのジアリール−２−（５ｈ）−フラノン
CA2211320C (en) * 1995-01-31 2007-03-20 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
JP3267300B2 (ja) * 1995-02-13 2002-03-18 ジー．ディー．サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide

Also Published As

Publication number Publication date
EP0956009B9 (en) 2002-12-11
TR199901120T2 (xx) 1999-07-21
NO992374L (no) 1999-07-21
NZ335726A (en) 2000-10-27
EP0956009A1 (en) 1999-11-17
BR9714303A (pt) 2000-04-25
US7226948B2 (en) 2007-06-05
DE69710224D1 (de) 2002-03-14
JP2001505206A (ja) 2001-04-17
PT956009E (pt) 2002-07-31
WO1998022104A3 (en) 1998-10-08
CA2272249A1 (en) 1998-05-28
NO992374D0 (no) 1999-05-18
US5985930A (en) 1999-11-16
SK67199A3 (en) 2001-01-18
US6649811B2 (en) 2003-11-18
AU725141B2 (en) 2000-10-05
ATE212546T1 (de) 2002-02-15
US20020162130A1 (en) 2002-10-31
ES2172822T3 (es) 2002-10-01
US20060059576A1 (en) 2006-03-16
IL129949A (en) 2003-05-29
IL129949A0 (en) 2000-02-29
WO1998022104A2 (en) 1998-05-28
EP0956009B1 (en) 2002-01-30
DE69710224T2 (de) 2002-10-02
KR20000069061A (ko) 2000-11-25
SK284334B6 (sk) 2005-02-04
AU5361298A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
DK0956009T3 (da) Behandling af neurodegenerative tilstande med nimesulid
MY117798A (en) Use of a rapamycin derivative in vasculopathies and xenotransplantation
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
IL140159A0 (en) Neuroprotective composition for the prevention and/or treatment of nervous and behavioral alterations due to anxiety states or depression
AU6232794A (en) The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
MXPA05006178A (es) Modificacion de la actividad de la ciclooxigenasa y de la lipooxigenasa con extractos de asteridae y opcionalmente acido boswelico.
ATE106183T1 (de) Biozide zusammensetzung und ihre verwendung.
FI961380A (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
DE69322750D1 (de) Dibekacin und Arbekacin Derivate wirksam gegen resistente Bakterien, und ihre Herstellung
DK0469477T3 (da) Antiallergisk kombination
DK0813870T3 (da) Anvendelse af darifenacin til at forstærke kognitive funktioner
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
DE69810629T2 (de) Beta-alkoxyacrylate gegen malaria
ATE228304T1 (de) Synergistische fungizide und/oder bakterizide zusammensetzungen
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
NO20012777D0 (no) Anvendelse av riluzol ved behandling av akustiske traumer
BR0002640A (pt) Uso de simeticona para tratar colite ulcerativa
DE60015133D1 (de) Synergistische zusammensetzung von bioziden
DE29620397U1 (de) Verliersicherung von Bolzen, Schrauben o.dgl.
BR0013778A (pt) Uso de leptina na inibição de proliferação de célula endotelial
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
ITMI961070A0 (it) Prevenzione e trattamento delle infezioni virali topiche con perfluoropolietere o loro composizioni.
徐志宏 et al. NOTE ON TWO NEW SPECIES OF DISCODES FOERSTER (HYMENO-PTERA: ENCYRTIDAE)
HUP0300083A3 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
DE69933212D1 (de) Benzocarbazol und indenoindole derivate als östrogene agentien